Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.

K J Tracey1, H Wei, K R Manogue

  • 1Laboratory of Surgical Metabolism, New York Hospital-Cornell University Medical Center, New York, New York 10021.

The Journal of Experimental Medicine
|March 1, 1988
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is There More than One Erythropoietin Receptor? Can the Hematopoietic Effects of EPO Be Dissociated from the Organ-Protective Effects by Carbamylated Erythropoietin?: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242, 2004.

Journal of the American Society of Nephrology : JASN·2023
Same author

The unexpected pathway to the creation of the HbA1c test and the discovery of AGE's.

Journal of internal medicine·2012
Same author

The value of failure: the discovery of TNF and its natural inhibitor erythropoietin.

Journal of internal medicine·2010
Same author

Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response.

Journal of internal medicine·2008
Same author

Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise.

Kidney international·2006
Same author

Erythropoietin: a candidate compound for neuroprotection in schizophrenia.

Molecular psychiatry·2003

Cachectin (TNF) induces cachexia, a wasting syndrome, in rats. This study shows cachectin causes weight loss, anemia, and inflammation, mimicking symptoms seen in cancer and chronic inflammation.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Pathophysiology

Background:

  • Cachexia is a lethal syndrome linked to chronic inflammation and cancer.
  • Cachectin/TNF is a suspected mediator of cachexia, but its in vivo effects are unknown.

Purpose of the Study:

  • To investigate the chronic in vivo effects of cachectin/TNF in a normal host model.

Main Methods:

  • Sublethal doses of recombinant human cachectin were administered to rats for 7-10 days.
  • Evaluated food intake, body weight, body composition, and blood parameters.
  • Conducted histopathological examination of various organs.

Main Results:

  • Cachectin administration induced cachexia, characterized by reduced food intake, weight loss, and depletion of lipid and protein stores.

Related Experiment Videos

  • Significant anemia (decreased red blood cell mass) and leukocytosis were observed.
  • Histopathology revealed tissue injury and inflammation in organs like the liver, spleen, and heart.

    • Conclusions:

    • Cachectin exposure can induce a cachexia, anemia, and inflammation syndrome in normal hosts.
    • These findings suggest cachectin/TNF plays a critical role in the pathophysiology of cachexia associated with inflammation and malignancy.